VAXCYTE, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
VAXCYTE, INC. (PCVX) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-04.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2025-11-04
- VAXCYTE, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- VAXCYTE, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-06-30 was $0.00.
- VAXCYTE, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-03-31 was $17.57M.
- VAXCYTE, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-09-30 was $4.62M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month |
|---|---|---|---|
| 2025-09-30 | $0.00 10-Q · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2025-11-04 | $83.52M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-06 | $17.57M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $17.57M 10-Q · filed 2025-05-07 | ||
| 2024-09-30 | $4.62M 10-Q · filed 2025-11-04 | $4.62M derived: sum of 2 quarters · filed 2025-11-04 | $4.62M 10-Q · filed 2025-11-04 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-06 | $0.00 10-Q · filed 2025-08-06 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-07 | ||
| 2021-03-31 | $1.03M 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |